Inovio Pharmaceuticals (NYSE:INO) has closed a public offering in which it raised $4 million. It said in a statement that it will use the proceeds toward clinical trial and research and development expenses.
Inovio Pharmaceuticals, a Blue Bell, Pennsylvania synthetic vaccine developer, has three drugs in phase 2 clinical trials for cervical cancer, HIV and malaria.
Its phase 2 therapeutic vaccine for cervical cancer for women infected by the human papillomavirus (HPV) is designed to boost the vaccinated woman’s immune system and would prevent the virus from progressing to cancer. It has a large phase 2 study in the United States, Canada, Australia, South Korea and South Africa.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
It started out as VGX Pharmaceuticals, which Inovio CEO J. Joseph Kim launched with his Ph.D. professor David Weiner of the Perelman School of Medicine at the University of Pennsylvania, until it did a reverse merger with Inovio in 2009, which gave it a drug manufacturing base in Asia.
